Pituitary Masterclass 2019

Friday 18th – Saturday 19th October 2019 San Raffaele Congress Centre, Milan, Italy

The Programme

An educational programme with extensive opportunities for audience participation, sharing and learning through experiences and asking questions to peers and experts.

The Masterclass will start at 12:00 on Friday 18th October and finish at 15:45 on Saturday 19th October. There will be a dinner for all attendees on Friday 18th October.

The detailed programme can be found here: Pituitary Masterclass

The programme will cover the following areas:

• Opening Lecture: Neurosurgery

Plenary Sessions:

• Acromegaly
• PTCOE (Pituitary Tumours Centre of Excellence)
• Cushing’s Disease
• Novel Treatments in pituitary disease
• Special clinical issues in pituitary disease

Meet the Expert Sessions:

• Management of pituitary adenomas
• Outcomes in pituitary adenomas
• Patient session: Acromegaly FAQs

Breakout sessions:

• Aggressive pituitary tumours
• Diabetes insipidus
• Pituitary imaging

Disclosures

SCIENTIFIC COMMITTEE

• Prof Andrea Giustina has the following relevant financial information to disclose: Grants/Consultancy (Abiogen, Astellas, Ipsen, Novartis, Pfizer)
• Prof Felipe Casanueva has the following relevant financial information to disclose: Grants/Consultancy (Ipsen)
• Prof Philippe Chanson has the following relevant financial information to disclose: Grants (Ipsen, Novartis, Novo-Nordisk, Pfizer, Tiburio)
• Prof Maria Fleseriu has the following relevant financial information to disclose: Grants/Consultancy (Chiasma, Ionis, Ipsen, Millendo, Novartis, Novo-Nordisk, Pfizer, Strongbridge)
• Prof Stephan Petersenn has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novartis, Pfizer)

FACULTY

• Prof Pietro Mortini does not have any relevant financial relationship to disclose
• Prof Anton Luger has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novo-Nordisk, Novartis, Pfizer, Sandoz)
• Prof Marco Losa does not have any relevant financial relationship to disclose
• Prof Stefano Frara has the following relevant financial information to disclose: Grants/Consultancy (Ipsen)
• Prof Nienke Biermasz does not have any relevant financial relationship to disclose
• Dr Francesco Tecilazich does not have any relevant financial relationship to disclose
• Dr Anna Formenti has the following relevant financial information to disclose: Grants/Consultancy (Abiogen, Sandoz)
• Prof Luca Persani has the following relevant financial information to disclose: Grants/Consultancy (Merck-Serono, Sandoz)
• Prof Monika Marazuela does not have any relevant financial relationship to disclose
• Prof Martin Reincke does not have any relevant financial relationship to disclose
• Prof Ezio Ghigo does not have any relevant financial relationship to disclose
• Prof AnaMaria Colao has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novartis, Pfizer)
• Prof Thierry Brue has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novartis, Pfizer)
• Prof Laura DeMarinis does not have any relevant financial relationship to disclose
• Dr Eugene Resmini does not have any relevant financial relationship to disclose
• Prof Prof Niki Karavitaki has the following relevant financial information to disclose: Grants/Consultancy (Novartis, Pfizer)
• Prof Paolo Loli does not have any relevant financial relationship to disclose
• Dr Raphael Souillard-Scemama does not have any relevant financial relationship to disclose

PLANNING COMMITTEE

• Iain Murdoch of COR2ED has the following relevant financial information to disclose: Shareholder (AstraZeneca)

This programme is supported by an Independent Educational Grant from Ipsen